ISRCTN81164554已完成不适用
Adjuvant cyclophosphamide, methotrexate and 5-Fluorouracil (CMF) versus 5-Fluorouracil, epirubicin and cyclosphosphamide (FEC) in node negative poor-risk primary breast cancer
Pharmacia Ltd & Upjohn (UK)0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Aged less than 65 years
- •2. Histologically proven invasive adenocarcinoma axillary nodes must be histologically negative
- •3. Tumour is T1c to T3
- •4. Tumour shows one of the following features of poor prognosis:
- •4.1. Oestrogen receptor less than or equal to 10 fmol/mg cytosol protein
- •4.2. Grade III
- •4.3. Vessel invasive
- •4.4. High labelling index of S phase
- •4.5. Aneuploidy
- •4.6. Tumour size at least 2 cm
- •5. Adequate renal, hepatic and haematological function
- •6. No evidence of metastatic disease
- •7. No evidence of inflammatory carcinoma
- •8. Patients with bilateral malignancy or with a mass in the opposite breast, unless there is biopsy proof that it is not a malignancy, are excluded
- •9. Patients with findings that relate them to a category of more advanced disease are not eligible
- •10. Patients with clinically positive nodes in the axilla opposite the affected breast, or with palpable supraclavicular or infraclavicular nodes are considered ineligible unless there is a biopsy evidence that these are not involved with the tumour
- •11. No previous or concomitant malignancy, except squamous or basal cell carcinoma which has been effectively treated and carcinoma in situ of the cervix which has been treated operatively
- •12. No prior therapy for the present breast cancer including radiotherapy, chemotherapy, immunotherapy and/or hormonal therapy
- •13. No non-malignant systemic disease which would preclude their being subjected to any of the treatment options or prevent prolonged follow up
- •14. No active or previous cardiac disease that would preclude the use of 4-epidoxorubicin
- •12. No psychiatric or addictive disorders which should preclude obtaining informed consent
排除标准
- •Not provided at time of registration
研究者
相似试验
已完成
不适用
Docetaxel plus cyclophophamide as adjuvant chemotherapy for negative axillary lymph node breast cancerBreast CancerJPRN-UMIN000001076Kinki Multidisciplinary Breast Oncology Group35
Unknown
3 期
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)Breast CancerNCT01031030Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS800
进行中（未招募）
不适用
Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre randomised phase II studyEUCTR2011-004146-18-GBThe Royal Marsden NHS Foundation Trust186
进行中（未招募）
不适用
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Elderly Patients with Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial'Diffuse Large-Bcell LymphomaMedDRA version: 14.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-001100-40-ITCELL THERAPEUTICS INC. SEDE SECONDARIA280
进行中（未招募）
不适用
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) andCyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) inPatients with Diffuse Large-B-cell Lymphoma: A Phase II, Randomized,Multicenter, Comparative TrialDiffuse large B-cell lymphoma.MedDRA version: 13.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-001100-40-DECell Therapeutics Europe S.r.l.280